GLP-1 Drugs for PCOS: What the Evidence Shows

Why women with PCOS are being prescribed Ozempic

If your doctor recently brought up semaglutide as part of your PCOS management, you're not alone. Truveta data shows that semaglutide and tirzepatide prescriptions among women with PCOS rose from 2.4% of the PCOS patient population in 2021 to 17.6% in 2025. That's a 637% relative increase in four years.

The reason isn't that these drugs are approved for PCOS — they're not. It's that a significant subset of PCOS is driven by insulin resistance, and these drugs treat insulin resistance more effectively than most alternatives. For women in that specific subset, the results can be meaningful.

What GLP-1 drugs actually do in PCOS

The 2025 meta-analysis in Scientific Reports — which pooled data from multiple randomized controlled trials — found that GLP-1 receptor agonists in women with PCOS produced significant reductions in waist circumference, BMI, triglycerides, and total testosterone compared to placebo. These are not trivial outcomes. Lowering free testosterone in PCOS directly addresses androgen-driven symptoms like hirsutism, acne, and hair thinning.

The testosterone reduction is particularly interesting because it may not be entirely explained by weight loss. GLP-1 receptors have been identified in ovarian tissue and granulosa cells, which suggests these drugs may have a direct effect on ovarian androgen production — not just an indirect effect via improved insulin sensitivity. The research on this mechanism is early, but it's a genuine finding, not a marketing claim.

What GLP-1 drugs don't address: the non-metabolic phenotypes of PCOS. Not all PCOS is driven by insulin resistance. Women with lean PCOS or predominantly adrenal androgen patterns may see less benefit. This is genuinely complicated, and it's worth understanding which phenotype you have before assuming these drugs will help your specific symptoms.

The critical conversation before starting

Three things that need to be on the table with your OB-GYN or endocrinologist.

First: insurance. Most insurers will not cover GLP-1 drugs for PCOS alone. You typically need a concurrent diagnosis of obesity (BMI over 30) or type 2 diabetes. This creates a frustrating access barrier for lean or lower-BMI women with PCOS who may still have insulin resistance.

Second: fertility. GLP-1 agonists are classified as potentially teratogenic in animal studies. Current guidance is to discontinue at least two months before attempting pregnancy. For women with PCOS who are actively trying to conceive, this timing matters.

Third: these are not a permanent fix. The metabolic and hormonal benefits seen in trials largely depend on continued use and concurrent lifestyle changes. Stopping the drug typically reverses the metabolic gains over time.

What to tell your doctor

• 💬 Ask your endocrinologist or OB-GYN specifically whether your PCOS phenotype is likely to respond to GLP-1 therapy — insulin-resistant and metabolic phenotypes see more benefit than adrenal or non-metabolic patterns.
• 💬 If you're considering pregnancy in the next 1–2 years, discuss the washout period explicitly — current guidance recommends stopping at least 2 months before trying to conceive.
• 💬 If insurance won't cover the drug for PCOS, ask about inositol or metformin as evidence-backed alternatives with a different mechanism (see our article on inositol vs. metformin for PCOS).
• 💬 Ask for a fasting insulin and HOMA-IR test to confirm whether insulin resistance is actually driving your PCOS — this helps clarify whether you're a strong candidate for this class of drugs.